8-苄基-1,3,8-三氮杂-螺[4.5]葵-4-酮 | 170921-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 8-苄基-1,3,8-三氮杂-螺[4.5]葵-4-酮
• 中文别名: 8-苄基-1,3,8-三氮杂螺[4.5]癸烷-4-酮
• 英文名称: 8-benzyl-1,3,8-triazaspiro<4.5>decan-4-one
• 英文别名: 8-benzyl-1,3,8-triaza-spiro[4,5]decan-4-one；8-Benzyl-1,3,8-triazaspiro[4.5]decan-4-one
• CAS: 170921-48-9
• 化学式: C₁₄H₁₉N₃O
• 分子量: 245.324
• InChiKey: BCWSNKPUZNJPGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  70-72 °C
• 沸点：
  451.4±45.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存条件：2-8℃，请密封保存，并置于干燥阴凉处避光。

反应信息

• 作为反应物：
  描述：

  8-苄基-1,3,8-三氮杂-螺[4.5]葵-4-酮 在 palladium on activated charcoal 盐酸 、 氢气 、 potassium carbonate 、 potassium iodide 作用下， 以 various solvent(s) 为溶剂， 25.0~80.0 ℃ 、275.79 kPa 条件下， 反应 44.0h， 生成 8-[4-(4-Fluoro-phenyl)-4-oxo-butyl]-1,3,8-triaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  Spiperone:  Influence of Spiro Ring Substituents on 5-HT_2A Serotonin Receptor Binding

  摘要：

  Spiperone (1) is a widely used pharmacological tool that acts as a potent dopamine D-2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Although spiperone also binds at 5-HT2C receptors, it is one of the very few agents that display some (ca. 1000-fold) binding selectivity for 5-HT2A versus 5-HT2C receptors and, hence, might serve as a useful template for the development of novel 5-HT2A antagonists if the impact of its various substituent groups on binding was known. In the present investigation we focused on the 1,3,8-triazaspiro[4.5]decanone portion of spiperone and found that replacement of the N-1-phenyl group with a methyl group only slightly decreased affinity for cloned rat 5-HT2A receptors. However, N-1-methyl derivatives displayed significantly reduced affinity for 5-HT1A, 5-HT2C, and dopamine D-2 receptors. Several representative examples were shown to behave as 5-HT2 antagonists. As such, N-1-alkyl analogues of spiperone may afford entry into a novel series of 5-HT2A-selective antagonists.

  DOI：

  10.1021/jm980452a
• 作为产物：
  描述：

  4-氨基-1-苄基哌啶-4-甲腈 在 sodium tetrahydroborate 、 硫酸 作用下， 反应 26.0h， 生成 8-苄基-1,3,8-三氮杂-螺[4.5]葵-4-酮
  参考文献：
  名称：

  Spiperone:  Influence of Spiro Ring Substituents on 5-HT_2A Serotonin Receptor Binding

  摘要：

  Spiperone (1) is a widely used pharmacological tool that acts as a potent dopamine D-2, serotonin 5-HT1A, and serotonin 5-HT2A antagonist. Although spiperone also binds at 5-HT2C receptors, it is one of the very few agents that display some (ca. 1000-fold) binding selectivity for 5-HT2A versus 5-HT2C receptors and, hence, might serve as a useful template for the development of novel 5-HT2A antagonists if the impact of its various substituent groups on binding was known. In the present investigation we focused on the 1,3,8-triazaspiro[4.5]decanone portion of spiperone and found that replacement of the N-1-phenyl group with a methyl group only slightly decreased affinity for cloned rat 5-HT2A receptors. However, N-1-methyl derivatives displayed significantly reduced affinity for 5-HT1A, 5-HT2C, and dopamine D-2 receptors. Several representative examples were shown to behave as 5-HT2 antagonists. As such, N-1-alkyl analogues of spiperone may afford entry into a novel series of 5-HT2A-selective antagonists.

  DOI：

  10.1021/jm980452a

文献信息

• [EN] TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS<br/>[FR] DERIVES DE TRIAZA-SPIROPIPERIDINE A UTILISER COMME INHIBITEURS DE GLYT-1 DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES ET NEUROPSYCHIATRIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005040166A1

  公开（公告）日：2005-05-06

  The invention relates to compounds of the general formula (I), wherein A-A is -CH2-CH2-, -CH2-CH2-CH2-, -CH2-0- or -0-CH2-; x is hydrogen or hydroxy; R1 is aryl or heteroaryl, unsubstituted or substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl; R2 is aryl or heteroaryl, unsubstituted or substituted by one or more substituents, selected from the group consisting of lower alkyl, lower alkoxy, halogen or trifluoromethyl, or is lower alkyl, -(CH2)n-­cycloalkyl, -(CH2)n-CF3, -(CH2)p-0-lower alkyl, -(CH2)1,2-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy or trifluoromethyl, or is -(CH2)p-NRR', wherein W and R' form together with the N-atom a heterocyclic ring, selected from the group consisting of piperidine, morpholine, thiomorpholine or 1, I-dioxo thiomorpholine; R3, R4 are independently from each other hydrogen, lower alkyl, phenyl or benzyl; R5 is hydrogen, lower alkyl or benzyl; R6 is hydrogen or lower alkyl; n is 0, 1 or 2; and p is 2 or 3; and to pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  该发明涉及一般式(I)的化合物，其中A-A为-CH2-CH2-，-CH2-CH2-CH2-，-CH2-0-或-0-CH2-；x为氢或羟基；R1为芳基或杂环芳基，未取代或由一个或多个取代基取代，所选取自较低烷基、较低烷氧基、卤素或三氟甲基的群组；R2为芳基或杂环芳基，未取代或由一个或多个取代基取代，所选取自较低烷基、较低烷氧基、卤素或三氟甲基的群组，或为较低烷基、-(CH2)n-环烷基、-(CH2)n-CF3、-(CH2)p-0-较低烷基、-(CH2)1,2-苯基，或者可由卤素、较低烷基、较低烷氧基或三氟甲基取代的苯基，或为-(CH2)p-NRR'，其中W和R'与N原子一起形成选自哌啶、吗啉、硫代吗啉或1,1-二氧硫代吗啉的杂环环的环；R3、R4相互独立为氢、较低烷基、苯基或苄基；R5为氢、较低烷基或苄基；R6为氢或较低烷基；n为0、1或2；p为2或3；以及其药用可接受的酸盐，用于治疗精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症和其他认知过程受损的疾病，如注意力缺陷障碍或阿尔茨海默病。
• Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broad-Spectrum Antiviral Activity against Influenza Strains
  作者：Matthew C. O'Reilly、Thomas H. Oguin、Sarah A. Scott、Paul G. Thomas、Charles W. Locuson、Ryan D. Morrison、J. Scott Daniels、H. Alex Brown、Craig W. Lindsley

  DOI：10.1002/cmdc.201402333

  日期：2014.12

  (PLD1/2) inhibitors afforded ML395 (VU0468809), a potent, >80‐fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50>30 000 nM; cellular PLD2, IC50=360 nM). Moreover, ML395 possesses an attractive in vitro DMPK profile, improved physiochemical properties, ancillary pharmacology (Eurofins Panel) cleaner than any other reported PLD inhibitor, and has been found to possess interesting activity as an

  对卤肽衍生的双磷脂酶 D1/2 (PLD1/2) 抑制剂家族进行进一步化学优化，得到 ML395 (VU0468809)，一种有效的、>80 倍 PLD2 选择性变构抑制剂（细胞 PLD1，IC 50 >30 000 n M；蜂窝 PLD2，IC 50 =360 n M )。此外，ML395 具有有吸引力的体外 DMPK 特征、改善的理化特性、辅助药理学（Eurofins Panel）比任何其他报道的 PLD 抑制剂更清洁，并且已发现在针对一系列流感毒株的细胞测定中作为抗病毒剂具有有趣的活性（H1、H3、H5 和 H7）。
• Triaza-spiropiperidine derivatives
  申请人：Ceccarelli Maria Simona

  公开号：US20050107373A1

  公开（公告）日：2005-05-19

  The invention relates to compounds of the general formula wherein A-A is —CH 2 —CH 2 —, —CH 2 —CH 2 —CH 2 —, —CH 2 —O— or —O—CH 2 —; and X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , n, and p are as defined herein, or a pharmaceutically acceptable salt thereof for the treatment of psychoses, pain, neurodegenerative dysfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

  本发明涉及一般式化合物，其中A-A为—CH2—CH2—，—CH2—CH2—CH2—，—CH2—O—或—O—CH2—；X、R1、R2、R3、R4、R5、R6、n和p如本文所定义，或其药学上可接受的盐，用于治疗精神病、疼痛、记忆和学习的神经退行性功能障碍、精神分裂症、痴呆症和其他认知过程受损的疾病，如注意力缺陷障碍或阿尔茨海默病。
• ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Shipps, JR. Gerald W.

  公开号：US20120328691A1

  公开（公告）日：2012-12-27

  The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

  本发明涉及式（I）的新型苯胺哌嗪衍生物，包含该苯胺哌嗪衍生物的组合物，以及使用该苯胺哌嗪衍生物治疗或预防增生性疾病、癌症、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病、真菌感染或与蛋白激酶活性相关的疾病的方法。
• SUBSTITUIERTE 1,3,8-TRIAZA-SPIRO(4,5)-DECAN-4-ON-DERIVATE ALS VORSTUFEN ZUR HERSTELLUNG VON PHARMAZEUTIKA
  申请人：CIS BIO INTERNATIONAL

  公开号：EP0745082A1

  公开（公告）日：1996-12-04